Gokhan Gorgisen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gokhan Gorgisen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Cigdem Aydin Acar
Burdur Mehmet Akif Ersoy University
3 shared publications - Zehra Kaya
Department of Medical Biology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey
3 shared publications - Gökhan Oto
Van Yuzuncu Yil Universitesi
2 shared publications Ismail Musab Gulacar
Department of Medical Biology, Faculty of Medicine, Van Yuzuncu Yil University, Van 65080, Turkey
2 shared publications- Osman Nidai Özeş
ALTAY Biopharma, San Bruno, CA, USA
2 shared publications A. Arslan
Department of Medical Biology, Van Yuzuncu Yil University Medical School, Van, Turkey
1 shared publication
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in Discover Oncology
An integrated bioinformatics and cell line study of NTN1 expression and tumor microenvironment associations in stomach adenocarcinoma
- 31 October 2026
- Published by Springer Nature in Discover Oncology
Open AccessAn integrated bioinformatics and cell line study of NTN1 expression and tumor microenvironment associations in stomach adenocarcinoma
- 9 February 2026
- Published by Academician Publishing
- p. 33-46
Pyroptosis: Cellular Signaling of Inflammatory Cell Death
Pyroptosis is a highly inflammatory form of programmed cell death characterized by cell swelling, membrane rupture, and release of pro-inflammatory mediators such as IL-1β and IL-18. Distinct from apoptosis, pyroptosis is primarily mediated by gasdermin family proteins, particularly Gasdermin D (GSDMD), which forms membrane pores upon activation. Signaling occurs via canonical pathways involving caspase-1 and inflammasomes (e.g., NLRP3) or non-canonical pathways via caspases-4/5/11 in response to intracellular LPS. Tight regulatory mechanisms, including endogenous inhibitors and feedback loops, control pyroptosis to prevent excessive inflammation. This review focuses on the cellular mechanism of pyroptosis and its inhibitors.
- 9 February 2026
- Published by Academician Publishing
- p. 33-46
Pyroptosis: Cellular Signaling of Inflammatory Cell Death
Pyroptosis is a highly inflammatory form of programmed cell death characterized by cell swelling, membrane rupture, and release of pro-inflammatory mediators such as IL-1β and IL-18. Distinct from apoptosis, pyroptosis is primarily mediated by gasdermin family proteins, particularly Gasdermin D (GSDMD), which forms membrane pores upon activation. Signaling occurs via canonical pathways involving caspase-1 and inflammasomes (e.g., NLRP3) or non-canonical pathways via caspases-4/5/11 in response to intracellular LPS. Tight regulatory mechanisms, including endogenous inhibitors and feedback loops, control pyroptosis to prevent excessive inflammation. This review focuses on the cellular mechanism of pyroptosis and its inhibitors.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
Tomato- and olive-derived proteins, hydrolysates and peptides in anticancer research: molecular findings and research gaps
Among the reviewed candidates, TCMPs and LLPSY have the clearest molecular definition and direct experimental support. Physiological exposure and in vivo validation remain major gaps.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
Open AccessTomato- and olive-derived proteins, hydrolysates and peptides in anticancer research: molecular findings and research gaps
Among the reviewed candidates, TCMPs and LLPSY have the clearest molecular definition and direct experimental support. Physiological exposure and in vivo validation remain major gaps.
- 26 September 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111759
Biogenic Ag/AgCl nanocomposites induce apoptosis via mitochondrial pathway and reduce size of 3D HT29 colorectal cancer spheroids
- 26 September 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111759
Biogenic Ag/AgCl nanocomposites induce apoptosis via mitochondrial pathway and reduce size of 3D HT29 colorectal cancer spheroids
- 12 December 2024
- Published by Springer Nature
- p. 123-152
Nutraceuticals in Metabolic Syndrome and Diabetes
- 12 December 2024
- Published by Springer Nature
- p. 123-152
Nutraceuticals in Metabolic Syndrome and Diabetes
- 4 July 2024
- Published by Nobel Tip Kitabevleri
- p. 153-170
Spinal Muscular Atrophy (SMA): Clinical Characteristics, Molecular Mechanisms and Treatment
Spinal Muscular Atrophy (SMA) is an otosomal recessive genetic disorder characterized by the degeneration of motor neurons, leading to muscle weakness and atrophy. It is predominantly caused by mutations or deletions in the SMN1 gene, resulting in insufficient levels of functional SMN protein, which is crucial for motor neuron survival and function. The clinical presentation of SMA varies from severe infantile onset with early mortality (Type 0 and Type 1) to milder adult forms (Type 4). Phenotype of patients can be modified by SMN2 gene copy numbers. Molecular diagnosis of SMA involves genetic testing techniques like qPCR and MLPA to identify SMN1/2 gene mutations and deletions. Treatment options include FDA-approved therapies such as Nusinersen, Onasemnogene abeparvovec, and Risdiplam, which aim to increase SMN protein levels and improve patient outcomes, with early intervention being key to better prognosis.
- 4 July 2024
- Published by Nobel Tip Kitabevleri
- p. 153-170
Spinal Muscular Atrophy (SMA): Clinical Characteristics, Molecular Mechanisms and Treatment
Spinal Muscular Atrophy (SMA) is an otosomal recessive genetic disorder characterized by the degeneration of motor neurons, leading to muscle weakness and atrophy. It is predominantly caused by mutations or deletions in the SMN1 gene, resulting in insufficient levels of functional SMN protein, which is crucial for motor neuron survival and function. The clinical presentation of SMA varies from severe infantile onset with early mortality (Type 0 and Type 1) to milder adult forms (Type 4). Phenotype of patients can be modified by SMN2 gene copy numbers. Molecular diagnosis of SMA involves genetic testing techniques like qPCR and MLPA to identify SMN1/2 gene mutations and deletions. Treatment options include FDA-approved therapies such as Nusinersen, Onasemnogene abeparvovec, and Risdiplam, which aim to increase SMN protein levels and improve patient outcomes, with early intervention being key to better prognosis.
- Open Access
- 19 September 2022
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (10) , 1-20
The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival
Endometrial cancer (EC) is the most common type of gynecologic cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with high-risk EC tumors is poor, indicating a need for novel therapies. The MEK5-ERK5 pathway is activated in response to growth factors and to different stressors, including oxidative stress and cytokines. Previous evidence supports a role for the MEK5-ERK5 pathway in the pathology of several cancers. We investigated the role of ERK5 in EC. In silico analysis of the PanCancer Atlas dataset showed alterations in components of the MEK5-ERK5 pathway in 48% of EC patients. Here, we show that ERK5 inhibition or silencing decreased EGF-induced EC cell proliferation, and that genetic deletion of MEK5 resulted in EC impaired proliferation and reduced tumor growth capacity in nude mice. Pharmacologic inhibition or ERK5 silencing impaired NF-kB pathway in EC cells and xenografts. Furthermore, we found a positive correlation between ERK5 and p65/RELA protein levels in human EC tumor samples. Mechanistically, genetic or pharmacologic impairment of ERK5 resulted in downregulation of NEMO/IKKγ expression, leading to impaired p65/RELA activity and to apoptosis in EC cells and xenografts, which was rescued by NEMO/IKKγ overexpression. Notably, ERK5 inhibition, MEK5 deletion or NF-kB inhibition sensitized EC cells to standard EC chemotherapy (paclitaxel/carboplatin) toxicity, whereas ERK5 inhibition synergized with paclitaxel to reduce tumor xenograft growth in mice. Together, our results suggest that the ERK5-NEMO-NF-κB pathway mediates EC cell proliferation and survival. We propose the ERK5/NF-κB axis as new target for EC treatment.
- 19 September 2022
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (10) , 1-20
Open AccessThe ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival
Endometrial cancer (EC) is the most common type of gynecologic cancer in women of developed countries. Despite surgery combined with chemo-/radiotherapy regimens, overall survival of patients with high-risk EC tumors is poor, indicating a need for novel therapies. The MEK5-ERK5 pathway is activated in response to growth factors and to different stressors, including oxidative stress and cytokines. Previous evidence supports a role for the MEK5-ERK5 pathway in the pathology of several cancers. We investigated the role of ERK5 in EC. In silico analysis of the PanCancer Atlas dataset showed alterations in components of the MEK5-ERK5 pathway in 48% of EC patients. Here, we show that ERK5 inhibition or silencing decreased EGF-induced EC cell proliferation, and that genetic deletion of MEK5 resulted in EC impaired proliferation and reduced tumor growth capacity in nude mice. Pharmacologic inhibition or ERK5 silencing impaired NF-kB pathway in EC cells and xenografts. Furthermore, we found a positive correlation between ERK5 and p65/RELA protein levels in human EC tumor samples. Mechanistically, genetic or pharmacologic impairment of ERK5 resulted in downregulation of NEMO/IKKγ expression, leading to impaired p65/RELA activity and to apoptosis in EC cells and xenografts, which was rescued by NEMO/IKKγ overexpression. Notably, ERK5 inhibition, MEK5 deletion or NF-kB inhibition sensitized EC cells to standard EC chemotherapy (paclitaxel/carboplatin) toxicity, whereas ERK5 inhibition synergized with paclitaxel to reduce tumor xenograft growth in mice. Together, our results suggest that the ERK5-NEMO-NF-κB pathway mediates EC cell proliferation and survival. We propose the ERK5/NF-κB axis as new target for EC treatment.
- Open Access
- 30 December 2021
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 14 (3) , 298-303
No Association Between IRS2 Gly1057Asp Polymorphism and Esophageal Cancer
Introduction: The aim of this study was to figure out the relationship between IRS2 Gly1057Asp variant and susceptibility to esophageal cancer. Material and Methods: A case-control study was conducted to select 70 esophageal cancer patients and 100 healthy control samples. Genomic DNA was extracted from peripheral whole blood samples and real time polymerase chain reaction (RT-PCR) based SNP genotyping was performed using predesigned Taqman assay. Results: There was no significant difference in the frequency distribution of genotypes between patients and control group. Conclusion: There is no significant correlation between the IRS2 Gly1057Asp variant and the risk of esophageal cancer.
- 30 December 2021
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 14 (3) , 298-303
Open AccessNo Association Between IRS2 Gly1057Asp Polymorphism and Esophageal Cancer
Introduction: The aim of this study was to figure out the relationship between IRS2 Gly1057Asp variant and susceptibility to esophageal cancer. Material and Methods: A case-control study was conducted to select 70 esophageal cancer patients and 100 healthy control samples. Genomic DNA was extracted from peripheral whole blood samples and real time polymerase chain reaction (RT-PCR) based SNP genotyping was performed using predesigned Taqman assay. Results: There was no significant difference in the frequency distribution of genotypes between patients and control group. Conclusion: There is no significant correlation between the IRS2 Gly1057Asp variant and the risk of esophageal cancer.
- 15 December 2020
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 35 (1) , 83-91
Relationship between MTHFR Gene Polymorphisms and Gastrointestinal Tumors Development: Perspective from Eastern Part of Turkey
Gastric and esophageal cancers are 2 of the most prevalent cancer types worldwide. Polymorphisms in the genes that code the methylenetetrahydrofolate reductase (MTHFR) enzyme increase the formation of both cancer types. In this study, it was aimed to research the relationship between the existence of MTHFR C677T and A1298C polymorphisms in patients with gastric and esophageal cancer and the lifespans of patients. This prospective study was performed at Van Yuzuncu Yil University. Included in the study were 30 patients with esophageal tumors, 70 patients with gastric tumors, and 61 healthy volunteers. From each of the patients, 5 mL of blood was drawn. DNA was isolated via kits with spin-column technology. It was concluded that the risk of developing gastric cancer was 4.13 times higher in individuals who had the AC genotype of the A1298C polymorphism when compared to those who had the AA genotype, while the risk was 2.91 times higher in individuals who had the CC genotype when compared to those who had the AA genotype (P = 0.001, P = 0.027). Carriers of the AC genotype of the A1298C polymorphism had 2.89 times higher risk of developing esophageal cancer when compared to those who had the AA genotype (P = 0.033). It was determined that individuals who had the 1298 CC genotype were not at higher risk of developing esophageal cancer when compared to those with the AA genotype (P = 0.863). It was concluded that individuals who had the TT genotype of the C677T polymorphism were not at higher risk of developing gastric and esophageal cancers when compared to those who had the 677CC genotype (P > 0.05). There was no difference in terms of the life spans of the patients with regards to the genotypes (P > 0.05). The results showed that the A1298C polymorphism on the MTHFR gene can be a risk factor for gastric and esophageal cancer in eastern Turkey. These polymorphisms may have no effect on the life spans of the patients.
- 15 December 2020
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 35 (1) , 83-91
Relationship between MTHFR Gene Polymorphisms and Gastrointestinal Tumors Development: Perspective from Eastern Part of Turkey
Gastric and esophageal cancers are 2 of the most prevalent cancer types worldwide. Polymorphisms in the genes that code the methylenetetrahydrofolate reductase (MTHFR) enzyme increase the formation of both cancer types. In this study, it was aimed to research the relationship between the existence of MTHFR C677T and A1298C polymorphisms in patients with gastric and esophageal cancer and the lifespans of patients. This prospective study was performed at Van Yuzuncu Yil University. Included in the study were 30 patients with esophageal tumors, 70 patients with gastric tumors, and 61 healthy volunteers. From each of the patients, 5 mL of blood was drawn. DNA was isolated via kits with spin-column technology. It was concluded that the risk of developing gastric cancer was 4.13 times higher in individuals who had the AC genotype of the A1298C polymorphism when compared to those who had the AA genotype, while the risk was 2.91 times higher in individuals who had the CC genotype when compared to those who had the AA genotype (P = 0.001, P = 0.027). Carriers of the AC genotype of the A1298C polymorphism had 2.89 times higher risk of developing esophageal cancer when compared to those who had the AA genotype (P = 0.033). It was determined that individuals who had the 1298 CC genotype were not at higher risk of developing esophageal cancer when compared to those with the AA genotype (P = 0.863). It was concluded that individuals who had the TT genotype of the C677T polymorphism were not at higher risk of developing gastric and esophageal cancers when compared to those who had the 677CC genotype (P > 0.05). There was no difference in terms of the life spans of the patients with regards to the genotypes (P > 0.05). The results showed that the A1298C polymorphism on the MTHFR gene can be a risk factor for gastric and esophageal cancer in eastern Turkey. These polymorphisms may have no effect on the life spans of the patients.